A local drug delivery system based on visible light-cured glycol chitosan and doxorubicinâ
hydrochloride for thyroid cancer treatment in vitro and in vivo.
Drug Deliv
; 25(1): 1664-1671, 2018 Nov.
Article
em En
| MEDLINE
| ID: mdl-30183420
ABSTRACT
Systemic drug delivery systems (SDDSs) for thyroid cancer treatment are associated with serious side effects including nausea, anorexia, and hair loss as a result of damage to normal tissues. In this study, we investigated the feasibility of a local DDS (LDDS) based on visible light-cured glycol chitosan (GC) hydrogel and doxorubicinâ
hydrochloride (DOXâ
HCl), called GC10/DOX, on thyroid cancer treatment in vivo. Visible light irradiation increased the storage modulus and swelling ratio of the GC10/DOX hydrogel precursor. The release of DOXâ
HCl from GC10/DOX exhibited two unique patterns comprising an initial burst within 18 hours, followed by a controlled and sustained release thereafter. In vitro cell viability testing showed that GC10/DOX had a greater antitumor effect than free DOXâ
HCl and GC10 hydrogel controls. In vivo, local injection of GC10/DOX near tumor tissue led to a superior antitumor effect compared with controls consisting of free DOXâ
HCl intravenously injected to the tail vein of thyroid cancer-bearing mouse and GC10 hydrogel subcutaneously injected near the tumor. Altogether, our results suggest that GC10/DOX may have clinical potential for thyroid cancer treatment.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Glândula Tireoide
/
Doxorrubicina
/
Sistemas de Liberação de Medicamentos
/
Quitosana
/
Antibióticos Antineoplásicos
Limite:
Animals
/
Humans
/
Male
Idioma:
En
Revista:
Drug Deliv
Ano de publicação:
2018
Tipo de documento:
Article